http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2356830-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2005-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6df147122351f958ddb358244c9d4f5f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_036dcdffdbf701426b2cc29bd74e5cbe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2b194c017be3b5e8380f9252c45f4c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95a788709cfd20cf69a8f6bfbc4e1a3b |
| publicationDate | 2011-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2356830-T3 |
| titleOfInvention | BIOMARCATORS FOR PRESELECTION OF PATIENTS FOR ANTI-IGF-1R THERAPY. |
| abstract | A pharmaceutical composition for use in the treatment of a tumor in a mammalian patient with cancer, wherein the composition comprises an inhibitor of IGF1 R and in which the treatment comprises (a) selecting a mammalian patient having a tumor that expresses one or more of the following: (i) phosphorylation of insulin receptor substrate-1 (IRS-1) in tyrosine 896; (ii) phosphorylation of IRS-1 in tyrosine 612; or (iii) phosphorylation of IRS-1 in any tyrosine; and (b) administration to said patient of a therapeutically effective amount of an inhibitor of IGF1 R; wherein the inhibitory agent is: (i) an isolated antibody or antibody binding fragment thereof that specifically binds to human IGF1 R comprising three CDRs of a light chain variable region comprising amino acids 20-128 of SEC ID NO: 8 and three CDRs of a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10; (ii) an isolated antibody or antigen binding fragment thereof that specifically binds to human IGF1 R comprising three CDRs of a light chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 2, 4, 6 , 8, 19-28, 35-38, 43, 45 or 73-98; and three CDRs of a heavy chain immunoglobulin comprising the amino acid sequence of SEQ ID NO: 10, 12-18, 29-34, 39, 40, 41, 42, 44 or 58-72; or an isolated single chain antibody that specifically binds to human IGF1 R comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 46-51; or (iii) 5'-ATCTCTCCGCTTCCTTTC-3 '(SEQ ID NO: 99); 5'-ATCTCTCCGCTTCCTTTC-3 '(SEC ID No.: 100) or 5'-ATCTCTCCGCTTCCTTTC-3' (SEC ID NO: 101). |
| priorityDate | 2004-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 291.